Department of Gastroenterology, University Hospital of Larissa, Viopolis Mezourlo, 41110 Larissa, Greece
Mini Review
Advances in Biologic Therapies for Inflammatory Bowel Disease: Efficacy and Safety Profiles
Author(s): Andreas Migdanis*
Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition that
significantly impacts patients' quality of life. Biologic therapies have revolutionized the management of IBD by targeting specific components of
the immune system. This review provides an overview of the latest advances in biologic therapies for IBD, focusing on their efficacy and safety
profiles. Recent biologics, including anti-TNF agents, integrin inhibitors and IL-12/23 inhibitors, have shown substantial efficacy in inducing and
maintaining remission in IBD patients. However, their use is associated with potential risks, including infections and malignancies. Understanding
the benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes... Read More»
DOI:
10.37421/2476-1958.2024.9.207
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 